Publications

1. van Wijk LM, Vermeulen S, Meijers M, van Diest MF, Ter Haar NT, de Jonge MM, Solleveld-Westerink N, van Wezel T, van Gent DC, Kroep JR, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG. The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. Cancers (Basel). 2020 Sep 29;12(10):E2805. doi: 10.3390/cancers12102805.

2. Mesman RLS, Calléja FMGR, Hendriks G, Morolli B, Misovic B, Devilee P, van Asperen CJ, Vrieling H, Vreeswijk MPG. The functional impact of variants of uncertain significance in BRCA2. Genet Med. 2020 Aug;22(8):1355-1365. doi: 10.1038/s41436-020-0814-5. Epub 2020 May 13.

3. Sampadi B, Pines A, Munk S, Mišovic B, de Groot AJ, van de Water B, Olsen JV, Mullenders LHF, Vrieling H. Quantitative phosphoproteomics to unravel the cellular response to chemical stressors with different modes of action. Arch Toxicol. 2020 May;94(5):1655-1671. doi: 10.1007/s00204-020-02712-7. Epub 2020 Mar 18.

4. Meulemans L, Mesman RLS, Caputo SM, Krieger S, Guillaud-Bataille M, Caux-Moncoutier V, Léone M, Boutry-Kryza N, Sokolowska J, Révillion F, Delnatte C, Tubeuf H, Soukarieh O, Bonnet-Dorion F, Guibert V, Bronner M, Bourdon V, Lizard S, Vilquin P, Privat M, Drouet A, Grout C, Calléja FMGR, Golmard L, Vrieling H, Stoppa-Lyonnet D, Houdayer C, Frebourg T, Vreeswijk MPG, Martins A, Gaildrat P. Skipping nonsense to maintain function: the paradigm of BRCA2 exon 12. Cancer Res. 2020 Feb 11. pii: canres.2491.2019. doi: 10.1158/0008-5472.CAN-19-2491. 

5. Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, Theeuwsen R, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VWH, Neel BG, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG, van Diest PJ, Witteveen PO, Jonges T, Bos JL, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019 May;25(5):838-849. doi: 10.1038/s41591-019-0422-6. Epub 2019 Apr 22.

6. de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T.  Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. Clin Cancer Res. 2019 Feb 1;25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443.

7. Mesman RLS, Calléja FM, Hendriks G, Morolli B, Misovic B, Devilee P, van Asperen CJ, Vrieling H and MP Vreeswijk. The functional impact of variants of uncertain significance in BRCA2. Genetics in Medicine (2018) Jul 10. doi: 10.1038/s41436-018-0052-2.

8. Shimelis H, Mesman RL, …, Vrieling H, Monteiro AN, Goldgar DE, Carreira A, Vreeswijk MP and FJ Couch, BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. Cancer Res. (2017) Jun 1;77(11):2789-2799.

9. Boei JJ, Vermeulen S, Klein B, Hiemstra PS, Verhoosel RM, Jennen DG, Lahoz A, Gmuender H, Vrieling H. Xenobiotic metabolism in differentiated human bronchial epithelial cells. Arch Toxicol. (2017) May;91(5):2093-2105. doi: 10.1007/s00204-016-1868-7.

10. Hendriks G, Derr RS, Misovic B, Morolli B, Calléja FM, Vrieling H. The extended ToxTracker assay discriminates between induction of DNA damage, oxidative stress and protein misfolding. Toxicol Sci. (2016) Mar;150(1):190-203. doi: 10.1093/toxsci/kfv323.


All publications